GO:0047385 [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047385 describes the phosphatase activity that removes a phosphate group from the E1 subunit of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex, reactivating BCAA catabolism.
• The reaction is catalyzed by the mitochondrial phosphatase PPM1K (also known as PP2Cm or BCKDH phosphatase), which directly opposes BCKDH kinase (BCKDK).
• BCKDH phosphatase activity is a key regulatory node integrating branched-chain amino acid (BCAA) catabolism with lipid metabolism and ATP-citrate lyase activity.
• Loss of PPM1K function causes maple syrup urine disease (MSUD), a severe metabolic disorder with elevated branched-chain amino acids and neurotoxicity.
• Altered BCKDH phosphatase activity is linked to insulin resistance, type 2 diabetes, and metabolic crosstalk with pyruvate metabolism.
• Experimental models for studying GO:0047385 include PPM1K knockout, point-mutation knock-in, and overexpression cell lines, combined with metabolomics and phosphoproteomics.
Description
GO:0047385, [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity, is a molecular function that catalyzes the removal of a phosphate group from the E1 subunit of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex. This dephosphorylation event is essential for reactivating the BCKDH complex, which controls the rate-limiting step of branched-chain amino acid (BCAA) catabolism. The activity is mediated by the mitochondrial phosphatase PPM1K (also called PP2Cm), which counteracts the inhibitory phosphorylation by BCKDH kinase (BCKDK). Researchers study this term because it sits at the intersection of BCAA metabolism, energy homeostasis, and human disease, including maple syrup urine disease and type 2 diabetes. Understanding its regulation provides insight into metabolic disorders and potential therapeutic targets.
[3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity At A Glance
| GO ID | GO:0047385 |
|---|---|
| GO term | [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity |
| Ontology | molecular_function |
| Synonym | branched-chain 2-keto acid dehydrogenase phosphatase activity; branched-chain alpha-keto acid dehydrogenase phosphatase; branched-chain oxo-acid dehydrogenase phosphatase activity |
| Major function | Dephosphorylation and reactivation of the BCKDH complex E1 subunit |
| Catalytic reaction | H2O + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] + phosphate |
| Primary enzyme | PPM1K (PP2Cm) |
| Subcellular location | Mitochondrial matrix |
| Pathological relevance | Maple syrup urine disease, insulin resistance, type 2 diabetes |
What Is GO:0047385?
According to the Gene Ontology, GO:0047385 describes the catalysis of the reaction: H2O + O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] = L-seryl-[3-methyl-2-oxobutanoate dehydrogenase] + phosphate. In other words, it is the phosphatase activity that removes a phosphate group from a specific serine residue on the E1 component of the BCKDH complex, thereby restoring its catalytic function in BCAA catabolism.
Why Is [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity Important in Cell Biology?
GO:0047385 is critical because it controls the activity of the BCKDH complex, the rate-limiting enzyme for branched-chain amino acid catabolism. Dysregulation of this phosphatase activity leads to accumulation of branched-chain amino acids and their ketoacids, which are neurotoxic and contribute to metabolic diseases such as maple syrup urine disease and type 2 diabetes. Moreover, the BCKDH phosphatase PPM1K integrates BCAA catabolism with lipid synthesis via ATP-citrate lyase, highlighting its broader role in metabolic regulation.
• Regulates the rate-limiting step of BCAA catabolism by dephosphorylating and activating the BCKDH complex.
• Mutations in PPM1K cause maple syrup urine disease, a severe neurometabolic disorder.
• Altered BCKDH phosphatase activity is associated with insulin resistance and type 2 diabetes.
• Integrates BCAA catabolism with lipid metabolism through ATP-citrate lyase regulation.
• Modulates metabolic crosstalk between pyruvate and BCAA oxidation.
• Serves as a potential therapeutic target for metabolic disorders and cancer.
• Its activity can be studied using phosphospecific antibodies and metabolic flux assays.
• Provides a model for understanding mitochondrial phosphatase regulation.
What Happens During [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity?
Substrate recognition and binding
In simple terms: The phosphatase finds and binds to the phosphorylated BCKDH E1 protein.
The phosphatase PPM1K specifically recognizes the phosphorylated serine residue on the E1 subunit of the BCKDH complex. This interaction is mediated by the active site of PPM1K, which accommodates the phosphoserine moiety.
Catalytic dephosphorylation
In simple terms: The phosphate group is removed from the BCKDH E1 protein.
Upon binding, PPM1K catalyzes the hydrolysis of the phosphoester bond, releasing inorganic phosphate and restoring the serine hydroxyl group. This reaction requires a divalent metal ion, typically Mg2+, as a cofactor.
Reactivation of BCKDH complex
In simple terms: Removing the phosphate turns the BCKDH complex back on.
Dephosphorylation of the E1 subunit activates the BCKDH complex, allowing it to catalyze the oxidative decarboxylation of branched-chain alpha-ketoacids. This step is essential for the catabolism of leucine, isoleucine, and valine.
Integration with metabolic pathways
In simple terms: This activity helps balance BCAA breakdown with other metabolic processes.
BCKDH phosphatase activity is regulated in response to nutritional and hormonal signals, and it influences lipid metabolism by modulating ATP-citrate lyase activity. It also participates in metabolic crosstalk with pyruvate metabolism.
Key Genes Involved in GO:0047385 [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity
The following genes and proteins are directly involved in or regulate the [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity and its associated pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPM1K | Mitochondrial phosphatase that dephosphorylates BCKDH E1 | Primary enzyme for GO:0047385; mutations cause MSUD |
| BCKDHA | E1 alpha subunit of BCKDH complex | Substrate of PPM1K; mutations cause MSUD |
| BCKDHB | E1 beta subunit of BCKDH complex | Substrate of PPM1K; mutations cause MSUD |
| DBT | Dihydrolipoamide branched-chain transacylase E2 | Component of BCKDH complex |
| DLD | Dihydrolipoamide dehydrogenase E3 | Component of BCKDH complex |
| BCKDK | BCKDH kinase that phosphorylates and inhibits BCKDH | Opposes PPM1K; regulates BCAA catabolism |
| ACLY | ATP-citrate lyase | Regulated by BCKDH phosphatase activity |
| SLC7A5 | L-type amino acid transporter | Influences BCAA uptake and metabolism |
| SLC3A2 | Heavy chain of amino acid transporter | Influences BCAA uptake |
| BCAT1 | Branched-chain aminotransferase 1 | First step of BCAA catabolism |
| BCAT2 | Branched-chain aminotransferase 2 | First step of BCAA catabolism |
| MPC1 | Mitochondrial pyruvate carrier subunit | Influences BCAA catabolism crosstalk |
| MPC2 | Mitochondrial pyruvate carrier subunit | Influences BCAA catabolism crosstalk |
| PPARGC1A | PGC-1alpha, mitochondrial biogenesis regulator | May regulate BCKDH complex expression |
| SIRT1 | NAD-dependent deacetylase | May modulate BCAA metabolism |
| FOXO1 | Transcription factor | Regulates metabolic genes including BCAA enzymes |
| MTOR | mTOR kinase | Integrates nutrient signals with BCAA metabolism |
| IRS1 | Insulin receptor substrate 1 | Links insulin signaling to BCAA metabolism |
How Is [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity Regulated?
The activity of [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase is regulated by nutritional and hormonal signals. Insulin promotes BCKDH phosphatase activity, thereby enhancing BCAA catabolism, while in insulin-resistant states this regulation is impaired. The phosphatase PPM1K is also subject to transcriptional regulation and post-translational modifications that affect its stability and activity. Additionally, the balance between BCKDH kinase and phosphatase determines the phosphorylation state of the BCKDH complex and thus flux through BCAA catabolism.
[3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPM1K | Maple syrup urine disease | PPM1K knockout cell line; patient-derived fibroblasts |
| BCKDHA | Maple syrup urine disease | BCKDHA point-mutation knock-in mice |
| BCKDHB | Maple syrup urine disease | BCKDHB knockout cell models |
| BCKDK | Metabolic disorders, BCAA dysregulation | BCKDK overexpression or knockout cells |
| ACLY | Lipid metabolism, cancer | ACLY knockout or overexpression models |
Maple syrup urine disease (MSUD)
Mutations in PPM1K, the gene encoding the BCKDH phosphatase, cause a variant form of maple syrup urine disease characterized by elevated branched-chain amino acids and neurotoxicity. Loss of phosphatase activity leads to constitutive phosphorylation and inactivation of the BCKDH complex, mimicking the metabolic block seen in classic MSUD.
Type 2 diabetes and insulin resistance
Altered BCKDH phosphatase activity contributes to elevated circulating branched-chain amino acids, which are biomarkers and potential mediators of insulin resistance and type 2 diabetes. Impaired dephosphorylation of BCKDH reduces BCAA oxidation, promoting metabolic dysfunction.
Metabolic crosstalk with lipid metabolism
BCKDH phosphatase activity regulates ATP-citrate lyase, linking BCAA catabolism to de novo lipogenesis and lipid homeostasis. Dysregulation of this axis may contribute to hepatic steatosis and metabolic syndrome.
Cancer metabolism
BCAA catabolism is often reprogrammed in cancer, and BCKDH phosphatase activity may influence tumor growth by modulating nutrient availability and metabolic flux. Targeting this pathway is an area of active investigation.
From [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of PPM1K loss on BCAA catabolism? | PPM1K knockout cell line (e.g., HEK293T, HepG2) |
| How do MSUD-associated PPM1K mutations affect phosphatase activity? | Point-mutation knock-in cell lines expressing mutant PPM1K |
| Does restoring PPM1K activity rescue metabolic defects? | Knock-in of wild-type PPM1K in patient-derived cells |
| How does PPM1K interact with BCKDH complex? | Tagged knock-in of PPM1K (e.g., FLAG, GFP) for co-IP and imaging |
| What is the impact of PPM1K overexpression on lipid metabolism? | PPM1K overexpression cell lines |
| Can CRISPR screening identify modifiers of BCAA sensitivity? | Genome-wide CRISPR knockout library screening in BCAA-sensitive cells |
How to Study the [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Phosphorylation status of BCKDH E1 | Assessing PPM1K activity in cells |
| Targeted metabolomics | Levels of BCAAs and ketoacids | Diagnosing MSUD and metabolic disorders |
| In vitro phosphatase assay | Catalytic activity of PPM1K | Characterizing mutant enzymes |
| Western blot with phosphospecific antibodies | Phosphorylation of BCKDH E1 | Monitoring pathway activation |
| CRISPR knockout screening | Genes affecting BCAA sensitivity | Identifying novel regulators |
| RNA-seq | Transcriptional changes in BCAA metabolism genes | Evaluating cellular response to metabolic stress |
| Seahorse metabolic flux analysis | Mitochondrial respiration and BCAA oxidation | Functional assessment of BCKDH activity |
Phosphoproteomics
Phosphoproteomics can quantify the phosphorylation state of BCKDH E1 at the regulatory serine residue, providing a direct readout of phosphatase activity. This method is useful for assessing changes in response to genetic or pharmacological perturbations.
Metabolomics
Targeted metabolomics measures branched-chain amino acids and their ketoacids, reflecting flux through the BCKDH complex and the activity of its phosphatase. This approach is essential for linking genotype to metabolic phenotype.
Enzymatic activity assays
In vitro phosphatase assays using recombinant PPM1K and phosphorylated BCKDH E1 peptide substrates can directly measure catalytic activity. These assays are valuable for characterizing mutant enzymes.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate sensitivity to BCAA restriction or BCKDH inhibition, uncovering novel regulators of this pathway.
How CRISPR Can Be Used to Study GO:0047385 [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity
Knockout
CRISPR knockout of PPM1K in cell lines such as HepG2 or HEK293T abolishes BCKDH phosphatase activity, leading to increased phosphorylation of BCKDH E1 and reduced BCAA catabolism. These models are useful for studying the consequences of loss of function and for testing rescue strategies.
Point Mutation
Introducing patient-specific point mutations into PPM1K via CRISPR knock-in allows researchers to study the molecular basis of MSUD and to evaluate the pathogenicity of variants of uncertain significance. Such models can reveal how specific amino acid changes affect phosphatase activity and stability.
Knock-in
Knock-in of tagged PPM1K (e.g., FLAG or GFP) enables affinity purification and imaging of the phosphatase in its native context, facilitating the study of its interactions with the BCKDH complex and its subcellular localization.
Overexpression
CRISPR activation or lentiviral overexpression of PPM1K can enhance BCKDH phosphatase activity, promoting BCAA catabolism and reducing BCAA levels. This approach is useful for investigating the metabolic benefits of increased BCAA oxidation and for validating therapeutic targets.
How EDITGENE Supports [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity Research
Researchers studying [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease pathogenesis, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity research.
Frequently Asked Questions About [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity
What is GO:0047385?
GO:0047385 is the Gene Ontology term for [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity, the enzymatic removal of a phosphate group from the BCKDH complex E1 subunit.
What genes are involved in [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity?
The primary gene is PPM1K, which encodes the phosphatase. Other involved genes include BCKDHA, BCKDHB, BCKDK, and DBT.
Which enzyme catalyzes this reaction?
PPM1K (also known as PP2Cm) is the mitochondrial phosphatase that catalyzes this reaction.
What diseases are associated with defects in this activity?
Defects cause maple syrup urine disease, and altered activity is linked to type 2 diabetes and insulin resistance.
How is BCKDH phosphatase activity regulated?
It is regulated by nutritional and hormonal signals, including insulin, and by the opposing action of BCKDH kinase.
What is the substrate of [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase?
The substrate is the phosphorylated E1 subunit of the BCKDH complex, specifically O-phospho-L-seryl-[3-methyl-2-oxobutanoate dehydrogenase].
Can CRISPR be used to study this activity?
Yes, CRISPR knockout, knock-in, and overexpression models of PPM1K are widely used to study its function and disease relevance.
What are the symptoms of PPM1K-related MSUD?
Symptoms include elevated branched-chain amino acids, neurological impairment, and metabolic decompensation.
How can I measure BCKDH phosphatase activity?
Activity can be measured using in vitro phosphatase assays, phosphoproteomics, and metabolomics.
What model systems are available for studying this pathway?
Common models include PPM1K knockout cell lines, patient-derived fibroblasts, and knock-in mouse models.
Conclusion
GO:0047385, [3-methyl-2-oxobutanoate dehydrogenase (lipoamide)]-phosphatase activity, is a central regulatory function in branched-chain amino acid catabolism, mediated by PPM1K. Its proper regulation is essential for metabolic homeostasis, and its dysfunction contributes to maple syrup urine disease, insulin resistance, and other metabolic disorders. Continued research using CRISPR-based models and advanced omics will further elucidate its role and therapeutic potential.
References
- 1. White PJ et al.. 2021. Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street.. Mol Metab 52:101261 PMID: 34044180
- 2. White PJ et al.. 2018. The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase.. Cell Metab 27(6):1281-1293.e7 PMID: 29779826
- 3. Ferguson D et al.. 2023. Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.. Mol Metab 70:101694 PMID: 36801448
- 5. Kılıç M et al.. 2025. Expanding the Genetic Spectrum of PPM1K-Related Maple Syrup Urine Disease: A Novel Mutation.. Am J Med Genet A 197(7):e64037 PMID: 40047138
- 6. Harris RA et al.. 2005. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism.. J Nutr 135(6 Suppl):1527S-30S PMID: 15930464
- 7. Shimomura Y et al.. 2006. Branched-chain amino acid catabolism in exercise and liver disease.. J Nutr 136(1 Suppl):250S-3S PMID: 16365092
